Comera Life Sciences (CMRA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CMRA vs. VRPX, NEXI, SCPS, VAXX, ARDS, NAVB, EVLO, SMFL, GNCAQ, and GNCAShould you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include Virpax Pharmaceuticals (VRPX), NexImmune (NEXI), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Smart for Life (SMFL), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry. Comera Life Sciences vs. Its Competitors Virpax Pharmaceuticals NexImmune Scopus BioPharma Vaxxinity Aridis Pharmaceuticals Navidea Biopharmaceuticals Evelo Biosciences Smart for Life Genocea Biosciences Genocea Biosciences Comera Life Sciences (NASDAQ:CMRA) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership. Do analysts recommend CMRA or VRPX? Given Comera Life Sciences' higher possible upside, equities analysts plainly believe Comera Life Sciences is more favorable than Virpax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Comera Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, CMRA or VRPX? Comera Life Sciences has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Is CMRA or VRPX more profitable? Comera Life Sciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34%-338.29% Does the media refer more to CMRA or VRPX? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Virpax Pharmaceuticals Neutral Which has better valuation and earnings, CMRA or VRPX? Virpax Pharmaceuticals has lower revenue, but higher earnings than Comera Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00M0.00-$18MN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Do institutionals and insiders hold more shares of CMRA or VRPX? 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryComera Life Sciences beats Virpax Pharmaceuticals on 5 of the 9 factors compared between the two stocks. Get Comera Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart CMRA vs. The Competition Export to ExcelMetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3K$935.70M$5.70B$10.42BDividend YieldN/A4.84%5.78%4.69%P/E RatioN/A1.2375.6726.39Price / SalesN/A26.47540.28125.20Price / CashN/A17.6425.6730.68Price / BookN/A6.6112.826.40Net Income-$18M-$5.42M$3.29B$276.69M Comera Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRAComera Life SciencesN/AN/AN/AN/A$3K$1.00M0.002Gap DownVRPXVirpax Pharmaceuticals0.1516 of 5 stars$0.01+9.9%N/A-99.9%$15KN/A0.007NEXINexImmuneN/A$0.01flatN/A-99.9%$14KN/A0.0070SCPSScopus BioPharmaN/A$0.00flatN/A+0.0%$13KN/A0.009VAXXVaxxinityN/A$0.00flatN/A-50.0%$13KN/A0.0090ARDSAridis PharmaceuticalsN/A$0.00-84.6%N/AN/A$11KN/A0.0030Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00-80.0%N/A-80.0%$10K$8.13K0.0010Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120SMFLSmart for LifeN/A$0.00-90.0%N/A-93.2%$7K$11.11M0.00110Gap UpGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070 Related Companies and Tools Related Companies VRPX Competitors NEXI Competitors SCPS Competitors VAXX Competitors ARDS Competitors NAVB Competitors EVLO Competitors SMFL Competitors GNCAQ Competitors GNCA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMRA) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMRA Stock Alerts